New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

Burcu Isler, Yohei Doi, Robert A. Bonomo, David L. Paterson

研究成果: Article査読

152 被引用数 (Scopus)

抄録

Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels. As a result, CRAB is declared as the top priority pathogen by the World Health Organization for the investment in new drugs. This urgent need for new therapies, in combination with faster FDA approval process, accelerated new drug development and placed several drug candidates in the pipeline. This article reviews available information about the new drugs and other therapeutic options focusing on agents in clinical or late-stage preclinical studies for the treatment of CRAB, and it evaluates their expected benefits and potential shortcomings.

本文言語English
ジャーナルAntimicrobial agents and chemotherapy
63
1
DOI
出版ステータスPublished - 01-2019
外部発表はい

All Science Journal Classification (ASJC) codes

  • 薬理学
  • 薬理学(医学)
  • 感染症

フィンガープリント

「New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル